At Zeal Bio, Alan Bash recommended shutting down operations when the science failed to show sufficient conviction for investors. This tough but pragmatic decision, made sooner rather than later, was respected by investors as it prevented further capital loss on a non-viable program.

In a market favoring asset-centric biotech, Springtide VC remains focused on platform companies. This countercyclical strategy mitigates the binary risk of single-asset failure and allows for multiple "shots on goal" and diverse business models, such as partnerships or becoming a drug developer.

When Terns Pharmaceuticals released poor data for its obesity drug, its core investors and analysts framed it as a positive "clearing event." Instead of punishing the failure, they rewarded the company for its decisive focus on its highly promising CML asset. This shows sophisticated investors value resource allocation and strategic clarity over clinging to underperforming programs.

A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

Unlike PMs, directors make objective, portfolio-wide decisions, which may include defunding or shelving a product. A critical mental shift for aspiring directors is to stop tying personal and professional value to the success of one product and instead focus on the overall health of the business.

The venture creation strategy for platform biotechs isn't about finding one blockbuster drug. It's a binary bet: either the underlying scientific platform is sound and can repeatedly generate many medicines, or the entire concept fails. There is no middle ground of succeeding with just one product from the platform.

Seaport's strategy focuses on molecules with established efficacy, such as allopregnanolone. The core innovation is not discovering new biology but applying its "Glif" platform to solve delivery problems like oral administration and side effects. This model prioritizes technical and commercial enablement over high-risk biological discovery.

To manage the long, costly timeline of therapeutic development, a biotech can create revenue-generating subsidiaries. One can offer its platform as a service (like a CDMO), while another sells lower-regulation products like cosmetic ingredients for faster market entry. This provides crucial cash flow to sustain the core drug pipeline.